Why we need a global citizens’ assembly on gene editing
By Nicole Curato and Simon Niemeyer,
The Conversation
| 09. 17. 2020
Developments in gene editing are often met with moral panic. Every new announcement raises outrage over the audacity of scientists “playing God”. The existence of mutant mosquitoesand designer babies are often framed as threats – evidence that science fiction has crossed over into real life.
There are clear dangers when the language of fear and scandal hijack public conversations on complex matters. But this doesn’t mean we should leave the discussion on genome editing – the process of altering an organism’s genetic sequence to produce favourable characteristics or remove unwanted ones – solely to scientists.
That danger was sharply underscored in 2018, when a young Chinese researcher announced he had engineered the birth of what may very well be the first genetically modified humans. “I feel proud,” he told the public, a year before he was jailed for forgery.
And so we reach an impasse. As global leaders face pressure to regulate genome editing, questions about who drives these ethical debates persist. Should leaders listen to scientists, who may be vulnerable to moral blindness, or to the...
Related Articles
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...